Literature DB >> 16103255

Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy.

Jianping Dai1, Franck Losy, Anne-Marie Guinault, Carine Pages, Ignacio Anegon, Pascal Desgranges, Jean-Pierre Becquemin, Eric Allaire.   

Abstract

BACKGROUND: The cell response to transforming growth factor-beta1 (TGF-beta1), a multipotent cytokine with healing potential, varies according to tissue context. We have evaluated the ability of TGF-beta1 overexpression by endovascular gene therapy to stabilize abdominal aortic aneurysms (AAAs) already injured by inflammation and proteolysis. METHODS AND
RESULTS: Active TGF-beta1 overexpression was obtained in already-developed experimental AAAs in rats after endovascular delivery of an adenoviral construct encoding for a mutated form of active simian TGF-beta1 and in an explant model using human atherosclerotic AAA fragments incubated with recombinant active TGF-beta1. Transient exogenous TGF-beta1 overexpression by endovascular gene delivery was followed by induction of endogenous rat TGF-beta1. Overexpression of active TGF-beta1 in experimental AAAs was associated with diameter stabilization, preservation of medial elastin, decreased infiltration of monocyte-macrophages and T lymphocytes, and a decrease in matrix metalloproteinase-2 and -9, which was also observed in the explant model, in both thrombus and wall. In parallel with downregulation of the destructive process, active TGF-beta1 overexpression triggered endoluminal reconstruction, replacing the thrombus by a vascular smooth muscle cell-, collagen-, and elastin-rich intima.
CONCLUSIONS: Local TGF-beta1 self-induction after transient exogenous overexpression reprograms dilated aortas altered by inflammation and proteolysis and restores their ability to withstand arterial pressure without further dilation. This first demonstration of stabilization of expanding AAAs by delivery of a single multipotent self-promoting gene supports the view that endovascular gene therapy should be considered for treatment of aneurysms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103255     DOI: 10.1161/CIRCULATIONAHA.104.523357

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  48 in total

Review 1.  Tissue engineering and regenerative strategies to replicate biocomplexity of vascular elastic matrix assembly.

Authors:  Chris A Bashur; Lavanya Venkataraman; Anand Ramamurthi
Journal:  Tissue Eng Part B Rev       Date:  2012-03-02       Impact factor: 6.389

2.  Aligned electrospun scaffolds and elastogenic factors for vascular cell-mediated elastic matrix assembly.

Authors:  Chris A Bashur; Anand Ramamurthi
Journal:  J Tissue Eng Regen Med       Date:  2011-09-23       Impact factor: 3.963

3.  Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis.

Authors:  Wei Li; Qingle Li; Yang Jiao; Lingfeng Qin; Rahmat Ali; Jing Zhou; Jacopo Ferruzzi; Richard W Kim; Arnar Geirsson; Harry C Dietz; Stefan Offermanns; Jay D Humphrey; George Tellides
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

4.  Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development.

Authors:  Lars Maegdefessel; Junya Azuma; Ryuji Toh; Denis R Merk; Alicia Deng; Jocelyn T Chin; Uwe Raaz; Anke M Schoelmerich; Azad Raiesdana; Nicholas J Leeper; Michael V McConnell; Ronald L Dalman; Joshua M Spin; Philip S Tsao
Journal:  J Clin Invest       Date:  2012-01-24       Impact factor: 14.808

5.  TGF-β (Transforming Growth Factor-β) Signaling Protects the Thoracic and Abdominal Aorta From Angiotensin II-Induced Pathology by Distinct Mechanisms.

Authors:  Stoyan N Angelov; Jie Hong Hu; Hao Wei; Nathan Airhart; Minghui Shi; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

6.  Angiotensin II Receptor Antagonism Reduces Transforming Growth Factor Beta and Smad Signaling in Thoracic Aortic Aneurysm.

Authors:  Maria Nataatmadja; Jennifer West; Sulistiana Prabowo; Malcolm West
Journal:  Ochsner J       Date:  2013

7.  Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice.

Authors:  Jie Hong Hu; Hao Wei; Mia Jaffe; Nathan Airhart; Liang Du; Stoyan N Angelov; James Yan; Julie K Allen; Inkyung Kang; Thomas N Wight; Kate Fox; Alexandra Smith; Rachel Enstrom; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-22       Impact factor: 8.311

8.  Smooth muscle phenotypic modulation is an early event in aortic aneurysms.

Authors:  Gorav Ailawadi; Christopher W Moehle; Hong Pei; Sandra P Walton; Zequan Yang; Irving L Kron; Christine L Lau; Gary K Owens
Journal:  J Thorac Cardiovasc Surg       Date:  2009-12       Impact factor: 5.209

9.  Perspectives on stem cell-based elastic matrix regenerative therapies for abdominal aortic aneurysms.

Authors:  Chris A Bashur; Raj R Rao; Anand Ramamurthi
Journal:  Stem Cells Transl Med       Date:  2013-05-15       Impact factor: 6.940

10.  Decreased collagen and increased matrix metalloproteinase-13 in experimental abdominal aortic aneurysms in males compared with females.

Authors:  Brenda S Cho; Karen J Roelofs; John W Ford; Peter K Henke; Gilbert R Upchurch
Journal:  Surgery       Date:  2009-09-20       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.